Special Issue

HIV and Viral Hepatitis Prevention, Treatment and Coinfection, 2nd Edition

Message from the Guest Editors

Hepatitis C is a disease caused by HCV that infects the liver and causes inflammation. On the other hand, HIV progressively attacks and weakens the immune system, destroys CD4 cells and ultimately leads to AIDS, increasing vulnerability to opportunistic infections. According to the WHO, 37.7 million people live with HIV and approximately 600,000 people die from HIVrelated causes each year. As HCV and HIV share transmission routes, a large proportion of HCV-infected individuals are also coinfected with HIV. HIV/HCV coinfection increases the morbidity and mortality of patients with HIV due to the more aggressive progression of fibrosis and liver cirrhosis in coinfected individuals. For this Special Issue, we invite contributors to submit research on discovering drugs with novel mechanisms of action, developing vaccines with the capacity to generate humoral immunity (for example, stimulating naive B cells in large populations to induce broadly neutralizing antibodies based on HIV Env or HCV E2) or different formulations (i.e., microbicides), to provide effective tools in the treatment, prevention, and eradication of these viruses.

Guest Editors

Dr. Daniel Sepúlveda-Crespo

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Madrid. Spain

Dr. Salvador Resino

Unidad de Infección Viral e Inmunidad, Centro Nacional de Microbiología, Instituto de Salud Carlos III (Campus Majadahonda), Madrid, Spain

Deadline for manuscript submissions

25 December 2025



Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8
CiteScore 7.7
Indexed in PubMed



mdpi.com/si/246034

Pharmaceuticals
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
pharmaceuticals@mdpi.com

mdpi.com/journal/ pharmaceuticals





Pharmaceuticals

an Open Access Journal by MDPI

Impact Factor 4.8 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Because of your expertise in the field of drug sciences, I kindly invite you to consider publishing your current work, in the form of a research article or a review, in the open access electronic journal *Pharmaceuticals*. *Pharmaceuticals* is characterized by an active editorial board and a dynamic editorial staff. Manuscripts are peer-reviewed and a final decision is provided to authors within 4–6 weeks after submission. Papers are published on the web immediately after acceptance. For details on the submission process or any other matter, please do not hesitate to contact us.

We hope to handle your contribution to *Pharmaceuticals* soon.

Editor-in-Chief

Prof. Dr. Amélia Pilar Rauter

Departamento de Química e Bioquímica (DQB) e Centro de Química Estrutural (CQE), Institute of Molecular Sciences, Faculdade de Cièncias, Universidade de Lisboa, Lisboa, Portugal

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Pharmaceutical Science)

